FENC
Price
$10.70
Change
-$0.32 (-2.90%)
Updated
Jul 2, 04:59 PM (EDT)
Capitalization
374.85M
32 days until earnings call
Intraday BUY SELL Signals
SPRO
Price
$2.19
Change
-$0.08 (-3.54%)
Updated
Jul 2, 04:59 PM (EDT)
Capitalization
127.38M
38 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

FENC vs SPRO

FENC vs SPRO Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
FENC vs. SPRO commentary
Jul 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FENC is a Hold and SPRO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 05, 2026
Stock price -- (FENC: $11.02 vs. SPRO: $2.26)
Brand notoriety: FENC and SPRO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FENC: 280% vs. SPRO: 166%
Market capitalization -- FENC: $374.85M vs. SPRO: $127.38M
FENC [@Biotechnology] is valued at $374.85M. SPRO’s [@Biotechnology] market capitalization is $127.38M. The market cap for tickers in the [@Biotechnology] industry ranges from $134.02B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FENC’s FA Score shows that 0 FA rating(s) are green whileSPRO’s FA Score has 1 green FA rating(s).

  • FENC’s FA Score: 0 green, 5 red.
  • SPRO’s FA Score: 1 green, 4 red.
According to our system of comparison, SPRO is a better buy in the long-term than FENC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FENC’s TA Score shows that 5 TA indicator(s) are bullish while SPRO’s TA Score has 5 bullish TA indicator(s).

  • FENC’s TA Score: 5 bullish, 4 bearish.
  • SPRO’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, FENC is a better buy in the short-term than SPRO.

Price Growth

FENC (@Biotechnology) experienced а +4.45% price change this week, while SPRO (@Biotechnology) price change was +11.88% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.30%. For the same industry, the average monthly price growth was +5.93%, and the average quarterly price growth was +1921.84%.

Reported Earning Dates

FENC is expected to report earnings on Aug 06, 2026.

SPRO is expected to report earnings on Aug 12, 2026.

Industries' Descriptions

@Biotechnology (+2.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FENC($375M) has a higher market cap than SPRO($127M). FENC has higher P/E ratio than SPRO: FENC (64.14) vs SPRO (8.13). FENC YTD gains are higher at: 43.117 vs. SPRO (-3.004). SPRO has higher annual earnings (EBITDA): 14.2M vs. FENC (-6.67M). SPRO has more cash in the bank: 56.1M vs. FENC (40.2M). SPRO has less debt than FENC: SPRO (2.47M) vs FENC (19.4M). SPRO has higher revenues than FENC: SPRO (54.8M) vs FENC (51M).
FENCSPROFENC / SPRO
Capitalization375M127M295%
EBITDA-6.67M14.2M-47%
Gain YTD43.117-3.004-1,435%
P/E Ratio64.148.13789%
Revenue51M54.8M93%
Total Cash40.2M56.1M72%
Total Debt19.4M2.47M784%
FUNDAMENTALS RATINGS
FENC vs SPRO: Fundamental Ratings
FENC
SPRO
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
88
Overvalued
59
Fair valued
PROFIT vs RISK RATING
1..100
71100
SMR RATING
1..100
9927
PRICE GROWTH RATING
1..100
3875
P/E GROWTH RATING
1..100
9792
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SPRO's Valuation (59) in the Pharmaceuticals Major industry is in the same range as FENC (88) in the Biotechnology industry. This means that SPRO’s stock grew similarly to FENC’s over the last 12 months.

FENC's Profit vs Risk Rating (71) in the Biotechnology industry is in the same range as SPRO (100) in the Pharmaceuticals Major industry. This means that FENC’s stock grew similarly to SPRO’s over the last 12 months.

SPRO's SMR Rating (27) in the Pharmaceuticals Major industry is significantly better than the same rating for FENC (99) in the Biotechnology industry. This means that SPRO’s stock grew significantly faster than FENC’s over the last 12 months.

FENC's Price Growth Rating (38) in the Biotechnology industry is somewhat better than the same rating for SPRO (75) in the Pharmaceuticals Major industry. This means that FENC’s stock grew somewhat faster than SPRO’s over the last 12 months.

SPRO's P/E Growth Rating (92) in the Pharmaceuticals Major industry is in the same range as FENC (97) in the Biotechnology industry. This means that SPRO’s stock grew similarly to FENC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FENCSPRO
RSI
ODDS (%)
Bearish Trend 4 days ago
68%
Bullish Trend 4 days ago
67%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
80%
Bullish Trend 4 days ago
67%
Momentum
ODDS (%)
Bullish Trend 4 days ago
86%
Bullish Trend 4 days ago
70%
MACD
ODDS (%)
Bullish Trend 4 days ago
83%
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 4 days ago
74%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
81%
Bearish Trend 4 days ago
87%
Advances
ODDS (%)
Bullish Trend 10 days ago
75%
Bullish Trend 21 days ago
70%
Declines
ODDS (%)
Bearish Trend 26 days ago
78%
Bearish Trend 11 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
70%
Bullish Trend 4 days ago
82%
Aroon
ODDS (%)
Bullish Trend 4 days ago
75%
Bearish Trend 4 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
FENC
Daily Signal:
Gain/Loss:
SPRO
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PIOTX26.970.18
+0.67%
Victory Pioneer Core Equity A
AATIX19.850.09
+0.46%
Ancora/Thelen Small-Mid Cap I
FEQHX16.09N/A
N/A
Fidelity Hedged Equity
FDCAX52.85-0.22
-0.41%
Fidelity Capital Appreciation
MDOEX11.94-0.29
-2.37%
Morgan Stanley Developing Opportunity I

FENC and

Correlation & Price change

A.I.dvisor indicates that over the last year, FENC has been loosely correlated with IPHA. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if FENC jumps, then IPHA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FENC
1D Price
Change %
FENC100%
N/A
IPHA - FENC
41%
Loosely correlated
N/A
AMLX - FENC
37%
Loosely correlated
N/A
RZLT - FENC
37%
Loosely correlated
N/A
REPL - FENC
35%
Loosely correlated
N/A
TNXP - FENC
34%
Loosely correlated
N/A
More

SPRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, SPRO has been loosely correlated with CCXI. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRO jumps, then CCXI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPRO
1D Price
Change %
SPRO100%
N/A
CCXI - SPRO
48%
Loosely correlated
N/A
ASBP - SPRO
42%
Loosely correlated
N/A
RXRX - SPRO
33%
Loosely correlated
N/A
XENE - SPRO
32%
Poorly correlated
N/A
FENC - SPRO
31%
Poorly correlated
N/A
More